We followed with interest the study by Sanfilippo et al. \[[@CR1]\], a meta-analysis of pooled observational studies of severe sepsis and/or septic shock. The authors included 794 patients stratified by survivors/non-survivor and showed that global longitudinal strain (GLS) measurements were strongly associated with survival (standard mean difference (SMD) − 0.26; 95% confidence interval (CI) − 0.47, − 0.04; *p* = 0.02).

We bring to your attention the significant inherent variability of GLS measurements in the context of proprietary differences in image acquisition platforms and inter-vendor variability in speckle tracking algorithms.

As the pooled data was comprised of four different vendor platforms, interpretation of pooled results should be done with abundant caution. It is notable that when the authors \[[@CR1]\] attempted sensitivity analysis grouping studies by vendors/software, such analysis was deemed not feasible.

We particularly emphasize that GLS standard mean difference (SMD) − 0.26 and 95% confidence interval (CI) − 0.47 and − 0.04 between survivors and non-survivors cited in the study \[[@CR1]\] should be interpreted with caution in the context of the existing literature: (a) Absolute difference between vendors for average GLS from the three apical views was up to 3.7% strain units \[[@CR2]\] and (b) inter-vendor 2D speckle tracking software variability limits of agreement range ± 3 to ± 4.5% in measuring GLS \[[@CR3]\].

The pooled standard mean difference was less than known inter-vendor variability.

Furthermore, longitudinal deformation is highest in the endocardium and lowest in the epicardium. Currently, there is insufficient evidence to decide if the endocardial, mid-wall, or full-wall strain is the best choice for clinical use \[[@CR4]\].

Although the methodology of meta-analysis is robust, the inherent variations in vendor protocols to measure strain, layer specific nature of strain measurements, patient characteristics, and known technical limitations in acquiring strain measurements limit the generalizability of results of such pooled data.

Another systematic review of GLS in severe sepsis/septic shock \[[@CR5]\] which analyzed a total of 455 patients did not combine the data by using meta-analysis methods citing significant methodological and statistical differences between the studies.

Until GLS measurements undergo further standardization in the future as being proposed by European Association of Cardiovascular Imaging (EACVI)-American Society of Echocardiography (ASE) strain standardization task force, this limitation continues to apply to currently available pooled data.

See related research by Sanfilippo et al., <https://ccforum.biomedcentral.com/articles/10.1186/s13054-018-2113-y>
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We thank Dr. Velagapudi and Tighe for their interest in our paper and for highlighting one of its limitations \[[@CR1]\]. Differences between inter-vendor software for evaluation of global longitudinal strain (GLS) were discussed in our study as one of the issues preventing to draw firm conclusions on our results. However, despite such variabilities, we believe that our results are still valid since the goal of studies included into our meta-analysis was not to give any cutoff value of strain that could differentiate between survivors and non-survivors, but rather to study the link between strain as a continuous value and prognosis.

However, in truth, there are other limitations in this and other meta-analyses in the field of echocardiography \[[@CR1], [@CR6]--[@CR8]\]. Among these, we believe that the most important one remains the lack of correction for confounding factors because these adjustments were never (or rarely) reported in the original studies included. Therefore, in common with most meta-analyses, our meta-analysis only suggests "associations" without the possibility to draw firm conclusions about "causative" mechanisms between the echocardiographic findings and outcomes. Nonetheless, these meta-analyses have also several advantages; the most important we believe are (1) suggesting directions for further echocardiography research through detection of hypothesis-generating associations and (2) highlighting the need for more structured reporting in the setting of critical care echocardiography research.

On a separate note, the correspondents also discuss in their letter the relevance of a small standardized mean difference (SMD) − 0.26 (95% confidence interval − 0.47, − 0.04) in the context of the already mentioned inter-vendor differences. It should be noted that, even if SMD does not correct for the variability between softwares, the Cochrane Handbook states that SMD is used in a meta-analysis when studies assess the same outcome but measure it in a variety of ways (i.e., using different scales). In these circumstances, SMD is necessary to standardize the results of the studies to a uniform scale before they can be combined. The SMD expresses the size of the intervention effect in each study relative to the variability observed in that study \[[@CR9]\]. Therefore, the statistical approach we used was the most appropriate to account for the variability of GLS. Furthermore, there are grounds to hypothesize that the use of SMD may have reduced the impact of inter-vendor differences.

More research is needed in critical care echocardiography; meta-analyses of non-randomized studies should not be taken at face value but as a driving force for further well-designed and focused research.
